This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Seth Alexander, Ph.D.
Director of RNA Technologies at Prime Medicine


Seth Alexander is a highly experienced organic chemist with a Ph.D and over 6 years of industry experience. His career in oligonucleotide therapeutics began as a postdoc where he co-invented a novel RNA labeling technology to site–specifically and covalently modify RNA. His first industry position was at Intellia Therapeutics (2017-2021) where he focused on developing Cas9 mRNA that made its way into clinical programs as well as guide RNA sequence and chemical modifications aimed at improving the therapeutic Index of Intellia's portfolio. Seth spent one year at Resilience (2021-2022) in process development building platform processes for the nucleic acids Franchise, before joining Prime Medicine in April of 2022. Seth's current role is to lead Prime’s RNA Technologies and Protein Sciences Teams which oversee the design and development of RNA and Protein prime editing components leveraged across the company.

Agenda Sessions

  • RNA-Based Approach to Delivering Prime Editing